NEWS
-
NEWS
Metcela announces issuance of second Japanese patent covering fibroblast-based cell therapy for the treatment of heart diseases
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announces that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6618066 to support the company’s technology of VCF (VCAM-1-positive Cardiac Fibroblast).
-
PRESS RELEASE
Metcela selected for J-Startup 2019, a government led initiative for supporting startups
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announces that the company was selected for J-Startup 2019, a public-private joint initiative for supporting startup. Read more…
-
MEDIA
Nikkei: “Revolutionize the way we treat heart failure”
Nikkei Sangyo Shinbun wrote an article on Metcela on 1st January, 2019 (Japanese)
https://www.nikkei.com/article/DGXMZO39653900U9A100C1000000/
-
NEWS
Metcela to take home the Grand Prize from Research Studio 2018 powered by SPARK
Metcela participated in “Research Studio 2018 powered by SPARK”, an acceleration program organized by Tsukuba Clinical Research & Development Organization (T-CReDO), and won the grand prize in the final pitch.
-
MEDIA
ASCII HealthTech: Using “living cells”, Metcela is developing an alternative heart failure therapy
ASCII HealthTech wrote an article about Metcela on 10th October, 2018 (Japanese)
-
PRESS RELEASE
Metcela Inc. announces receipt of NEDO’s Hashiwatashi Grant for VCF-1 autologous cellular therapy targeting heart failure patients
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announced today that the New Energy and Industrial Technology Development Organization (NEDO) has awarded the company with the Hashiwatashi grant (up to 100 million yen) to support research and development activities for VCAM-1-positive Cardiac Fibroblast (VCF-1), leading up to initiation of a clinical trial for heart failure patients in Japan.
-
PRESS RELEASE
Metcela raises 520 million yen in Series A financing round
With this financing, Metcela has now raised a total of 920 Million yen including the previous investments and grants
Metcela, a biotech startup specializing in fibroblast-based cell therapy for heart failure treatment, announced the successful closing of its 520 million yen ($4.6 million) Series A round. The round was led by Beyond Next Ventures, with additional participation from new investors, Eight Road Ventures Japan, F-Prime Capital Partners, Japan Lifeline Co., Ltd., Sony Innovation Fund, The Dai-ichi Life Insurance Company, Limited, and KSP Inc. With this financing, Metcela has raised a total sum of 920 million yen ($8.2 million), including previously raised investments and grants.
-
NEWS
Nikkei: Metcela confirmed the therapeutic effect on the heart failure medicine
Nikkei Shinbun wrote an article on Metcela on 18th September 2017 (Japanese).
https://www.nikkei.com/article/DGKKZO21214120V10C17A9TJE000/